EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gut microbiota, microbiota‐derived metabolites, and graft‐versus‐host disease

XiaoYan Yue, Hongyu Zhou, ShuFen Wang, Xu Chen, HaoWen Xiao iD

Cancer Medicine · 2024-02 · 13 (3)

DOI: 10.1002/cam4.6799 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 18.01.2024. Verfasst von XiaoYan Yue und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Microbiota, Graft vs Host Disease. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 183 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic hematopoietic stem cell transplantation is one of the most effective treatment strategies for leukemia, lymphoma, and other hematologic malignancies. However, graft‐versus‐host disease (GVHD) can significantly reduce the survival rate and quality of life of patients after transplantation, and is therefore the greatest obstacle to transplantation. The recent development of new technologies, including high‐throughput sequencing, metabolomics, and others, has facilitated great progress in understanding the complex interactions between gut microbiota, microbiota‐derived metabolites, and the host. Of these interactions, the relationship between gut microbiota, microbial‐associated metabolites, and GVHD has been most intensively researched. Studies have shown that GVHD patients often suffer from gut microbiota dysbiosis, which mainly manifests as decreased microbial diversity and changes in microbial composition and microbiota‐derived metabolites, both of which are significant predictors of poor prognosis in GVHD patients. Therefore, the purpose of this review is to summarize what is known regarding changes in gut microbiota and microbiota‐derived metabolites in GVHD, their relationship to GVHD prognosis, and corresponding clinical strategies designed to prevent microbial dysregulation and facilitate treatment of GVHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeMicrobiotaGraft vs Host DiseaseHumansQuality of LifeDysbiosis

Stichwörter der Autor:innen

allogeneic hematopoietic stem cell transplantationgraft-versus-host diseasegut microbiotamicrobiota-derived metabolites

Autor:innen und Institutionen

  • Department of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.

ORCID-Profile: HaoWen Xiao

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Yue, X., Zhou, H., Wang, S., Chen, X., & Xiao, H. (2024). Gut microbiota, microbiota‐derived metabolites, and graft‐versus‐host disease. Cancer Medicine, 13(3). https://doi.org/10.1002/cam4.6799

Vancouver

Yue X, Zhou H, Wang S, Chen X, Xiao H. Gut microbiota, microbiota‐derived metabolites, and graft‐versus‐host disease. Cancer Medicine. 2024;13(3). doi:10.1002/cam4.6799

BibTeX
@article{Yue2024,
  author = {Yue, XiaoYan and Zhou, Hongyu and Wang, ShuFen and Chen, Xu and Xiao, HaoWen},
  title = {Gut microbiota, microbiota‐derived metabolites, and graft‐versus‐host disease},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {3},
  doi = {10.1002/cam4.6799}
}
Kostenlos starten →